{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T12:30:28Z","timestamp":1794745828238,"version":"4.9.1"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T00:00:00Z","timestamp":1762300800000},"content-version":"vor","delay-in-days":308,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.clinsp.2025.100839","type":"journal-article","created":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T08:55:10Z","timestamp":1763369710000},"page":"100839","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Effects of pemafibrate (a selective PPAR-\u03b1 agonist) versus weight loss through an intensive lifestyle modification on liver enzymes, serum soluble dipeptidyl peptidase-4, and hepatic steatosis and fibrosis evaluated by FibroScan transient elastography in people with type 2 diabetes and MASLD"],"prefix":"10.1016","volume":"80","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-3639-5100","authenticated-orcid":false,"given":"Kanako","family":"Kato","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2907-261X","authenticated-orcid":false,"given":"Teruo","family":"Jojima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-6878-9981","authenticated-orcid":false,"given":"Dai","family":"Tanuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-7740-1543","authenticated-orcid":false,"given":"Kanako","family":"Suda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-9689-9363","authenticated-orcid":false,"given":"Shintaro","family":"Sakurai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4613-3744","authenticated-orcid":false,"given":"Toshie","family":"Iijima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0850-5655","authenticated-orcid":false,"given":"Takuya","family":"Tomaru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4720-4882","authenticated-orcid":false,"given":"Isao","family":"Usui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0610-1999","authenticated-orcid":false,"given":"Yoshimasa","family":"Aso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.clinsp.2025.100839_bib0001","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","volume":"81","author":"Liver;","year":"2024","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.clinsp.2025.100839_bib0002","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.2337\/dc10-2229","article-title":"Edinburgh Type 2 Diabetes Study Investigators. Prevalence of and risk factors for hepatic steatosis and nonalcoholic fatty liver disease in people with type 2 diabetes: the Edinburgh Type 2 Diabetes Study","volume":"34","author":"Williamson","year":"2011","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.clinsp.2025.100839_bib0003","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1053\/j.gastro.2020.11.051","article-title":"AGA clinical practice update on lifestyle modification using diet and exercise to achieve weight loss in the management of nonalcoholic fatty liver disease: expert review","volume":"160","author":"Younossi","year":"2021","journal-title":"Gastroenterology"},{"issue":"Suppl 2","key":"10.1016\/j.clinsp.2025.100839_bib0004","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/dom.14569","article-title":"Weight loss interventions and nonalcoholic fatty liver disease: optimizing liver outcomes","volume":"24","author":"Finer","year":"2022","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.clinsp.2025.100839_bib0005","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1146\/annurev.nutr.21.1.193","article-title":"Peroxisomal beta-oxidation and peroxisome proliferator-activated receptor alpha: an adaptive metabolic system","volume":"21","author":"Reddy","year":"2001","journal-title":"Annu Rev Nutr"},{"issue":"3","key":"10.1016\/j.clinsp.2025.100839_bib0006","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1172\/JCI27989","article-title":"Sorting out the roles of PPAR alpha in energy metabolism and vascular homeostasis","volume":"116","author":"Lefebvre","year":"2006","journal-title":"J Clin Invest"},{"issue":"19","key":"10.1016\/j.clinsp.2025.100839_bib0007","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1161\/01.CIR.98.19.2088","article-title":"Mechanism of action of fibrates on lipid and lipoprotein metabolism","volume":"98","author":"Staels","year":"1998","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.clinsp.2025.100839_bib0008","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.molmet.2014.02.002","article-title":"Integrated physiology and systems biology of PPAR\u03b1","volume":"3","author":"Kersten","year":"2014","journal-title":"Mol Metab"},{"issue":"9500","key":"10.1016\/j.clinsp.2025.100839_bib0009","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(05)67667-2","article-title":"FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomized controlled trial","volume":"366","author":"Keech","year":"2005","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.clinsp.2025.100839_bib0010","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1080\/17425255.2018.1483337","article-title":"Peroxisome proliferator-activated receptor alpha-mediated drug toxicity in the liver","volume":"14","author":"Hedrington","year":"2018","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.clinsp.2025.100839_bib0011","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/1475-2840-12-82","article-title":"Selective peroxisome proliferator-activated receptor \u03b1 modulators (SPPARM\u03b1): the next generation of peroxisome proliferator-activated receptor \u03b1-agonists","volume":"12","author":"Fruchart","year":"2013","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.clinsp.2025.100839_bib0012","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.atherosclerosis.2016.02.029","article-title":"K-877-04 Study Group. Effects of K-877, a novel selective ppar\u03b1 modulator (SPPARM\u03b1), in dyslipidaemic patients: a randomized, double blind, active- and placebo-controlled, phase 2 trial","volume":"249","author":"Ishibashi","year":"2016","journal-title":"Atherosclerosis"},{"issue":"1","key":"10.1016\/j.clinsp.2025.100839_bib0013","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jacl.2017.10.006","article-title":"K-877 Study Group. Efficacy and safety of pemafibrate (K-877), a selective peroxisome proliferator-activated receptor \u03b1 modulator, in patients with dyslipidemia: results from a 24-week, randomized, double blind, active-controlled, phase 3 trial","volume":"12","author":"Ishibashi","year":"2018","journal-title":"J Clin Lipidol"},{"issue":"12","key":"10.1016\/j.clinsp.2025.100839_bib0014","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1111\/hepr.13571","article-title":"Effect of pemafibrate on fatty acid levels and liver enzymes in non-alcoholic fatty liver disease patients with dyslipidemia: a single-arm, pilot study","volume":"50","author":"Seko","year":"2020","journal-title":"Hepatol Res"},{"issue":"3","key":"10.1016\/j.clinsp.2025.100839_bib0015","doi-asserted-by":"crossref","first-page":"270","DOI":"10.5114\/ceh.2020.99528","article-title":"Pemafibrate decreases markers of hepatic inflammation in patients with non-alcoholic fatty liver disease","volume":"6","author":"Shinozaki","year":"2020","journal-title":"Clin Exp Hepatol"},{"issue":"10","key":"10.1016\/j.clinsp.2025.100839_bib0016","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1111\/apt.16596","article-title":"Randomised clinical trial: pemafibrate, a novel selective peroxisome proliferator-activated receptor \u03b1 modulator (SPPARM\u03b1), versus placebo in patients with non-alcoholic fatty liver disease","volume":"54","author":"Nakajima","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.clinsp.2025.100839_bib0017","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/B978-0-12-385855-9.00003-5","article-title":"Dipeptidyl peptidase in autoimmune pathophysiology","volume":"53","author":"Ohnuma","year":"2011","journal-title":"Adv Clin Chem"},{"key":"10.1016\/j.clinsp.2025.100839_bib0018","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.trsl.2011.09.005","article-title":"Serum level of soluble CD26\/dipeptidyl peptidase-4 (DPP-4) predicts the response to sitagliptin, a DPP-4 inhibitor, in patients with type 2 diabetes controlled inadequately by metformin and\/or sulfonylurea","volume":"159","author":"Aso","year":"2012","journal-title":"Transl Res"},{"key":"10.1016\/j.clinsp.2025.100839_bib0019","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.trsl.2013.07.011","article-title":"The serum level of soluble CD26\/dipeptidyl peptidase 4 increases in response to acute hyperglycemia after an oral glucose load in healthy subjects: association with high-molecular weight adiponectin and hepatic enzymes","volume":"162","author":"Aso","year":"2013","journal-title":"Transl Res"},{"issue":"8","key":"10.1016\/j.clinsp.2025.100839_bib0020","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0012226","article-title":"Serum dipeptidyl peptidase-4 activity in insulin resistant patients with non-alcoholic fatty liver disease: a novel liver disease biomarker","volume":"5","author":"Firneisz","year":"2010","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.clinsp.2025.100839_bib0021","doi-asserted-by":"crossref","DOI":"10.1111\/ijcp.13335","article-title":"Impact of dapagliflozin, an SGLT2 inhibitor, on serum levels of soluble dipeptidyl peptidase-4 in patients with type 2 diabetes and non-alcoholic fatty liver disease","volume":"73","author":"Aso","year":"2019","journal-title":"Int J Clin Pract"},{"issue":"3","key":"10.1016\/j.clinsp.2025.100839_bib0022","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1007\/s13340-020-00485-z","article-title":"Effects of short-term calorie restriction on circulating DPP-4\/sCD26 concentrations and body composition in patients with type 2 diabetes","volume":"12","author":"Yamauchi","year":"2021","journal-title":"Diabetol Int"},{"issue":"7698","key":"10.1016\/j.clinsp.2025.100839_bib0023","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/nature26138","article-title":"Hepatocyte-secreted DPP4 in obesity promotes adipose inflammation and insulin resistance","volume":"555","author":"Ghorpade","year":"2018","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.clinsp.2025.100839_bib0024","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/dom.13520","article-title":"Evaluation of the effects of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease","volume":"21","author":"Shimizu","year":"2019","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"10.1016\/j.clinsp.2025.100839_bib0025","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/S2468-1253(19)30383-8","article-title":"FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study","volume":"5","author":"Newsome","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"9","key":"10.1016\/j.clinsp.2025.100839_bib0026","doi-asserted-by":"crossref","first-page":"E350","DOI":"10.1002\/oby.20300","article-title":"Early changes of abdominal adiposity detected with weekly dual bioelectrical impedance analysis during calorie restriction","volume":"21","author":"Ida","year":"2013","journal-title":"Obesity (Silver Spring)"},{"issue":"7","key":"10.1016\/j.clinsp.2025.100839_bib0027","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.2337\/db05-1525","article-title":"Comparison of serum high-molecular weight (HMW) adiponectin with total adiponectin concentrations in type 2 diabetic patients with coronary artery disease using a novel enzyme-linked immunosorbent assay to detect HMW adiponectin","volume":"55","author":"Aso","year":"2006","journal-title":"Diabetes"},{"issue":"10","key":"10.1016\/j.clinsp.2025.100839_bib0028","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1002\/jgh3.12650","article-title":"Effect of 48-week pemafibrate on non-alcoholic fatty liver disease with hypertriglyceridemia, as evaluated by the FibroScan-aspartate aminotransferase score","volume":"5","author":"Hatanaka","year":"2021","journal-title":"JGH Open"},{"issue":"3","key":"10.1016\/j.clinsp.2025.100839_bib0029","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1007\/s12072-022-10453-1","article-title":"Pemafibrate improves liver dysfunction and non-invasive surrogates for liver fibrosis in patients with non-alcoholic fatty liver disease with hypertriglyceridemia: a multicenter study","volume":"17","author":"Morishita","year":"2023","journal-title":"Hepatol Int"},{"issue":"6","key":"10.1016\/j.clinsp.2025.100839_bib0030","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1016\/j.jhep.2018.08.011","article-title":"Beneficial effects of lifestyle intervention in non-obese patients with non-alcoholic fatty liver disease","volume":"69","author":"Wong","year":"2018","journal-title":"J Hepatol"},{"issue":"21","key":"10.1016\/j.clinsp.2025.100839_bib0031","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1056\/NEJMoa2210645","article-title":"PROMINENT investigators. Triglyceride lowering with pemafibrate to reduce cardiovascular risk","volume":"387","author":"Das Pradhan","year":"2022","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.clinsp.2025.100839_bib0033","doi-asserted-by":"crossref","first-page":"7818","DOI":"10.1038\/s41598-020-64902-8","article-title":"Pemafibrate, a selective ppar\u03b1 modulator, prevents non-alcoholic steatohepatitis development without reducing the hepatic triglyceride content","volume":"10","author":"Sasaki","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.clinsp.2025.100839_bib0034","doi-asserted-by":"crossref","DOI":"10.1038\/srep42477","article-title":"Pemafibrate, a novel selective peroxisome proliferator-activated receptor alpha modulator, improves the pathogenesis in a rodent model of nonalcoholic steatohepatitis","volume":"7","author":"Honda","year":"2017","journal-title":"Sci Rep"},{"issue":"2","key":"10.1016\/j.clinsp.2025.100839_bib0035","doi-asserted-by":"crossref","first-page":"172","DOI":"10.5114\/ceh.2021.106864","article-title":"Pemafibrate improves hepatic inflammation, function and fibrosis in patients with non-alcoholic fatty liver disease: a one-year observational study","volume":"7","author":"Shinozaki","year":"2021","journal-title":"Clin Exp Hepatol"},{"issue":"5","key":"10.1016\/j.clinsp.2025.100839_bib0036","doi-asserted-by":"crossref","DOI":"10.1016\/j.jdiacomp.2021.107885","volume":"35","author":"Sagara","year":"2021","journal-title":"J Diabetes Complications"}],"container-title":["Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1807593225002571?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1807593225002571?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T19:45:14Z","timestamp":1790711114000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1807593225002571"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":35,"alternative-id":["S1807593225002571"],"URL":"https:\/\/doi.org\/10.1016\/j.clinsp.2025.100839","relation":{},"ISSN":["1807-5932"],"issn-type":[{"value":"1807-5932","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of pemafibrate (a selective PPAR-\u03b1 agonist) versus weight loss through an intensive lifestyle modification on liver enzymes, serum soluble dipeptidyl peptidase-4, and hepatic steatosis and fibrosis evaluated by FibroScan transient elastography in people with type 2 diabetes and MASLD","name":"articletitle","label":"Article Title"},{"value":"Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinsp.2025.100839","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 HCFMUSP. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}],"article-number":"100839"}}